Ralf Reilmann

List of Publications by Year in Descending Order

71 papers	4,641 citations	28 h-index	68 g-index
74 ext. papers	5,382 ext. citations	6.8 avg, IF	5.03 L-index

#	Paper	IF	Citations
71	Immediate effects of treadmill walking in individuals with Lewy body dementia and Huntington's disease. *Gait and Posture*, **2021**, 86, 186-191	2.6	1
70	Toward e-Scales: Digital Administration of the International Parkinson and Movement Disorder Society Rating Scales. *Movement Disorders Clinical Practice*, **2021**, 8, 208-214	2.2	2
69	Objectively characterizing Huntington's disease using a novel upper limb dexterity test. *Journal of Neurology*, **2021**, 268, 2550-2559	5.5	
68	Cognitive decline in Huntington's disease in the Digitalized Arithmetic Task (DAT). *PLoS ONE*, **2021**, 16, e0253064	3.7	1
67	Genotyping single nucleotide polymorphisms for allele-selective therapy in Huntington disease. *Neurology: Genetics*, **2020**, 6, e430	3.8	3
66	Gait variability as digital biomarker of disease severity in Huntington's disease. *Journal of Neurology* , **2020**, 267, 1594-1601	5.5	8
65	How specific are non-motor symptoms in the prodrome of Parkinson's disease compared to other movement disorders?. *Parkinsonism and Related Disorders*, **2020**, 81, 213-218	3.6	2
64	Impaired Isometric Force Matching in Upper and Lower Limbs Revealed by Quantitative Motor Assessments in Huntington's Disease. *Journal of Huntington's Disease*, **2019**, 8, 483-492	1.9	2
63	Application of Quantitative Motor Assessments in Friedreich Ataxia and Evaluation of Their Relation to Clinical Measures. *Cerebellum*, **2019**, 18, 896-909	4.3	7
62	How to evaluate effects of occupational therapy - lessons learned from an exploratory randomized controlled trial. *Parkinsonism and Related Disorders*, **2019**, 67, 42-47	3.6	1
61	Movement Disorder Society Task Force Viewpoint: Huntington's Disease Diagnostic Categories. *Movement Disorders Clinical Practice*, **2019**, 6, 541-546	2.2	30
60	Quantitative grip force assessment of muscular weakness in chronic inflammatory demyelinating polyneuropathy. *BMC Neurology*, **2019**, 19, 118	3.1	0
59	Physical Activity and Exercise Outcomes in Huntington Disease (PACE-HD): Protocol for a 12-Month Trial Within Cohort Evaluation of a Physical Activity Intervention in People With Huntington Disease. *Physical Therapy*, **2019**, 99, 1201-1210	3.3	5
58	A roadmap for implementation of patient-centered digital outcome measures in Parkinson's disease obtained using mobile health technologies. *Movement Disorders*, **2019**, 34, 657-663	7	115
57	The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age. *Movement Disorders*, **2019**, 34, 676-681	7	28
56	Defining pediatric huntington disease: Time to abandon the term Juvenile Huntington Disease?. *Movement Disorders*, **2019**, 34, 584-585	7	8
55	A Feasibility Study of Quantitative Motor Assessments in Children Using the Q-Motor Suite. *Journal of Huntington's Disease*, **2019**, 8, 333-338	1.9	0

54	Association of CAG Repeats With Long-term Progression in Huntington Disease. *JAMA Neurology*, **2019**, 76, 1375-1385	17.2	22
53	Parkinsonism in Huntington's disease. *International Review of Neurobiology*, **2019**, 149, 299-306	4.4	4
52	Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. *Lancet Neurology, The*, **2019**, 18, 165-176	24.1	50
51	Quantification of Motor Function in Huntington Disease Patients Using Wearable Sensor Devices. *Digital Biomarkers*, **2019**, 3, 103-115	7.1	13
50	Objective assessment of gait and posture in premanifest and manifest Huntington disease - A multi-center study. *Gait and Posture*, **2018**, 62, 451-457	2.6	11
49	Interrater Reliability of the Unified Huntington's Disease Rating Scale-Total Motor Score Certification. *Movement Disorders Clinical Practice*, **2018**, 5, 290-295	2.2	7
48	Stimulating neural plasticity with real-time fMRI neurofeedback in Huntington's disease: A proof of concept study. *Human Brain Mapping*, **2018**, 39, 1339-1353	5.9	24
47	Cross-sectional and longitudinal voxel-based grey matter asymmetries in Huntington's disease. *NeuroImage: Clinical*, **2018**, 17, 312-324	5.3	14
46	Huntington's disease: Current and future therapeutic prospects. *Movement Disorders*, **2018**, 33, 1033-1041	7	28
45	Minipigs as a Large-Brained Animal Model for Huntington's Disease: From Behavior and Imaging to Gene Therapy. *Methods in Molecular Biology*, **2018**, 1780, 241-266	1.4	2
44	Behavioral Assessment of Stress Compensation in Minipigs Transgenic for the Huntington Gene Using Cortisol Levels: A Proof-of-Concept Study. *Journal of Huntington's Disease*, **2018**, 7, 151-161	1.9	3
43	Does arterial hypertension influence the onset of Huntington's disease?. *PLoS ONE*, **2018**, 13, e0197975	3.7	4
42	Vocalisation as a Viable Assessment for Phenotyping Minipigs Transgenic for the Huntington Gene?. *Journal of Huntington's Disease*, **2018**, 7, 269-278	1.9	1
41	On the rise: Quantitative measures in Huntington's disease. *Movement Disorders*, **2018**, 33, 1370-1371	7	
40	Survival End Points for Huntington Disease Trials Prior to a Motor Diagnosis. *JAMA Neurology*, **2017**, 74, 1352-1360	17.2	10
39	Motor outcome measures in Huntington disease clinical trials. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2017**, 144, 209-225	3	28
38	Behavioral testing of minipigs transgenic for the Huntington gene-A three-year observational study. *PLoS ONE*, **2017**, 12, e0185970	3.7	17
37	E2 Progression of motor subtypes in huntington's disease: a six-year follow-up study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, A45.2-A45	5.5	

36	Behavioral phenotyping of minipigs transgenic for the Huntington gene. *Journal of Neuroscience Methods*, **2016**, 265, 34-45	3	15
35	Neuroimaging of a minipig model of Huntington's disease: Feasibility of volumetric, diffusion-weighted and spectroscopic assessments. *Journal of Neuroscience Methods*, **2016**, 265, 46-55	3	15
34	Technology in Parkinson's disease: Challenges and opportunities. *Movement Disorders*, **2016**, 31, 1272-82	7	305
33	A randomized, controlled trial of a multi-modal exercise intervention in Huntington's disease. *Parkinsonism and Related Disorders*, **2016**, 31, 46-52	3.6	49
32	Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study. *EBioMedicine*, **2015**, 2, 1420-9	8.8	91
31	Quantitative motor assessment of muscular weakness in myasthenia gravis: a pilot study. *BMC Neurology*, **2015**, 15, 265	3.1	8
30	Digitomotography in Parkinson's disease: a cross-sectional and longitudinal study. *PLoS ONE*, **2015**, 10, e0123914	3.7	17
29	A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers. *Movement Disorders*, **2015**, 30, 393-401	7	38
28	A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease. *Movement Disorders*, **2015**, 30, 427-31	7	57
27	The Libechov Minipig as a Large Animal Model for Preclinical Research in Huntington's disease – Thoughts and Perspectives. *Ceska A Slovenska Neurologie A Neurochirurgie*, **2015**, 78/111, 55-60	1.4	8
26	FDG-PET Fails to Detect a Disease-Specific Phenotype in Rats Transgenic for Huntington's Disease – A 15 Months Follow-up Study. *Journal of Huntington's Disease*, **2015**, 4, 37-47	1.9	2
25	Huntington disease: natural history, biomarkers and prospects for therapeutics. *Nature Reviews Neurology*, **2014**, 10, 204-16	15	600
24	Clinical trials in Huntington's disease: Interventions in early clinical development and newer methodological approaches. *Movement Disorders*, **2014**, 29, 1419-28	7	35
23	Huntington's disease: a field on the move. Introduction. *Movement Disorders*, **2014**, 29, 1333-4	7	3
22	Diagnostic criteria for Huntington's disease based on natural history. *Movement Disorders*, **2014**, 29, 1335-41	7	110
21	The structural correlates of functional deficits in early huntington's disease. *Human Brain Mapping*, **2013**, 34, 2141-53	5.9	65
20	Pharmacological treatment of chorea in Huntington's disease-good clinical practice versus evidence-based guideline. *Movement Disorders*, **2013**, 28, 1030-3	7	38
19	Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. *Lancet Neurology, The*, **2013**, 12, 637-49	24.1	557

18	Corpus callosal atrophy in premanifest and early Huntington's disease. *Journal of Huntington's Disease*, **2013**, 2, 517-26	1.9	21
17	Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy. *Human Brain Mapping*, **2013**, 34, 519-29	5.9	77
16	Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. *Lancet Neurology, The*, **2012**, 11, 42-53	24.1	392
15	Early changes in white matter pathways of the sensorimotor cortex in premanifest Huntington's disease. *Human Brain Mapping*, **2012**, 33, 203-12	5.9	104
14	Huntington's disease: objective assessment of posture--a link between motor and functional deficits. *Movement Disorders*, **2012**, 27, 555-9	7	18
13	An important step towards translation of stem cell therapies in clinical applications for neurodegenerative diseases and beyond?. *Movement Disorders*, **2012**, 27, 1355-6	7	
12	Huntington□ disease: Towards disease modification □Gaps and bridges, facts and opinions. *Basal Ganglia*, **2012**, 2, 241-248		7
11	Does chromatin modulation provide the first wet biomarker for Huntington's disease?. *Movement Disorders*, **2012**, 27, 473	7	
10	Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. *Lancet Neurology, The*, **2011**, 10, 31-42	24.1	443
9	Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet Neurology, The*, **2011**, 10, 1049-57	24.1	134
8	Progression of premanifest and early Huntington's disease detectable after 1 year□oes TRACK-HD open the door to disease-modifying trials in HD and beyond?. *Movement Disorders*, **2011**, 26, 605	7	
7	Assessment of involuntary choreatic movements in Huntington's disease--toward objective and quantitative measures. *Movement Disorders*, **2011**, 26, 2267-73	7	42
6	Self-awareness of motor dysfunction in patients with Huntington's disease in comparison to Parkinson's disease and cervical dystonia. *Journal of the International Neuropsychological Society*, **2011**, 17, 788-95	3.1	49
5	Tongue force analysis assesses motor phenotype in premanifest and symptomatic Huntington's disease. *Movement Disorders*, **2010**, 25, 2195-202	7	36
4	Grasping premanifest Huntington's disease - shaping new endpoints for new trials. *Movement Disorders*, **2010**, 25, 2858-62	7	37
3	Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. *Lancet Neurology, The*, **2009**, 8, 791-801	24.1	721
2	Coordination of prehensile forces during precision grip in Huntington's disease. *Experimental Neurology*, **2000**, 163, 136-48	5.7	67
1	Activity or Connectivity? Evaluating neurofeedback training in Huntington□ disease		4